Stadice

Stadice is an early-stage biotechnology company focused on developing novel small molecule inhibitors targeting the STAT3 (Signal Transducer and Activator of Transcription 3) pathway. STAT3 is a well-validated but historically difficult-to-drug target that plays a critical role in promoting tumor growth, survival, and immune evasion in various cancers. The company's lead programs aim to address high unmet needs in oncology and potentially inflammatory conditions by selectively blocking STAT3 activity. Stadice is leveraging its proprietary structural biology and medicinal chemistry expertise to overcome the challenges associated with targeting transcription factors.